Received Aug 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 5Y4TL | — |
Shingrix is valid as a patient received the first dose in 2018 and the second one in April 2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 73-year-old female patient who received Herpes zoster (Shingrix) (batch number 5Y4TL, expiry date 31-JAN-2027) for an unknown indication. Previously administered products included Shingrix (patient had 1st dose in 2018, with expiry 13 March 2019 and batch number G45LN.). On 30-APR-2025, the patient received the 2nd dose of Shingrix. On 30-APR-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Shingrix is valid as a patient received the first dose in 2018 and the second one in April 2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date: 06-AUG-2025 Other HCP reported that a patient received the first dose in 2018 and the second one in April 2025, which led to drug dose administration interval too long. The patients was 73 years of age at the time of reporting, female.